{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T23:21:32Z","timestamp":1747610492432},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>It is important to confirm CD30 expression in T-cell lymphoma cases, but immunohistochemical staining for CD30 is not commonly performed and no comparison has been done between the results of flow cytometry (FCM) and immunohistochemical staining for CD30. Therefore, we devised a notation that we termed proportion of immunoreactivity\/expression for FCM (PRIME-F notation), based on the cellular proportion showing different antigen-antibody reactivity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively compiled 211 cases of T-cell lymphoma, assessed via FCM, from major hospitals in Miyagi Prefecture from January 2012 to January 2019, and compared 52 of these cases with the immunohistochemical immunoreactive (IR) pattern of CD30 (PRIME-I notation). The PRIME-F notation was divided into five levels: notations starting with \u201c-\u201d followed by 3, 2, and 1 \u201c&gt;\u201d correspond to level-I, level-II, or level-III; notations starting with \u201c(dim)+\u201d correspond to level-IV; and those starting with \u201c+\u201d or \u201c(bright)+\u201d correspond to level-V.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The 52 cases of PRIME-F notation with \u201c+\u201d included 16 cases of peripheral T-cell lymphoma (PTCL\/NOS), 3 of follicular T-cell lymphoma (FTL), 3 of angioimmunoblastic T-cell lymphoma (AITL), 6 of extranodal NK\/T-cell lymphoma\/nasal type (ENKL), 18 of adult T-cell lymphoma (ATL), and 6 cases of anaplastic large cell lymphoma (ALCL). Eight of the 52 cases were immunohistochemically CD30-negative. In the PRIME-F level-I to III group (excluding false-positive cases), 21.7% (5 out of 23 cases) were\u2009&lt;\u200910% positive for CD30 upon immunohistochemistry (IHC). Contrarily, in the level-IV &amp; -V group, no CD30 positivity rate of &lt;\u200910% upon IHC was found (0%) (<jats:italic>p<\/jats:italic>\u2009=\u20090.0497). In level-IV, 42.9% of cases presented a CD30 negative rate\u00a0<jats:underline>&gt;<\/jats:underline>\u00a01\/3 upon IHC, while in level-V, only 7.1% (one out of 14 cases) did. The CD30 negative rate tended to be low (<jats:italic>p<\/jats:italic>\u2009=\u20090.0877) in level-V.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>To our knowledge, this is the first report describing the correspondence between FCM and immunohistochemistry findings for CD30 through newly proposed notations. The PRIME-F and PRIME-I notations for CD30 showed a minor positive correlation. The PRIME notation is considered universally applicable to antibodies, and notations of both FCM and IHC show great potential for big data.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-09098-4","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T14:05:17Z","timestamp":1640009117000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Utility of a new notation to visualize flow cytometry analysis results: first preliminary comparison with immunohistochemistry to detect CD30 expression on T-cell lymphoma cells"],"prefix":"10.1186","volume":"21","author":[{"given":"Fumiyoshi","family":"Fujishima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Katsushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Harigae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironobu","family":"Sasano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Ichinohasama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"key":"9098_CR1","first-page":"437","volume":"18","author":"E Nomura","year":"2004","unstructured":"Nomura E, Takagi S, Ichinohasama R, Kikuchi T, Shiraki M, Oomori S, et al. Multiparameter analysis for discreet differential diagnosis of mucosa-associated lymphoid tissue lymphoma in the intestine. In Vivo. 2004;18:437\u201341.","journal-title":"In Vivo"},{"key":"9098_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12886-015-0158-0","volume":"15","author":"K Maruyama","year":"2015","unstructured":"Maruyama K, Kunikata H, Sugita S, Mochizuki M, Ichinohasama R, Nakazawa T. First case of primary intraocular natural killer t-cell lymphoma. BMC Ophthalmol. 2015;15:169.","journal-title":"BMC Ophthalmol"},{"key":"9098_CR3","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1038\/sj.leu.2400802","volume":"11","author":"R Ichinohasama","year":"1997","unstructured":"Ichinohasama R, DeCoteau JF, Myers J, Kadin ME, Sawai T, Ooya K. Three-color flow cytometry in the diagnosis of malignant lymphoma based on the comparative cell morphology of lymphoma cells and reactive lymphocytes. Leukemia. 1997;11:1891\u2013903.","journal-title":"Leukemia."},{"key":"9098_CR4","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","volume":"98","author":"E Sabattini","year":"2013","unstructured":"Sabattini E, Pizzi M, Tabanelli V, Baldin P, Sacchetti CS, Agostinelli C, et al. CD30 expression in peripheral T-cell lymphomas. Haematologica. 2013;98:e81\u20132.","journal-title":"Haematologica."},{"key":"9098_CR5","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","volume":"125","author":"ED Jacobsen","year":"2015","unstructured":"Jacobsen ED, Sharman JP, Oki Y, Advani RH, Winter JN, Bello CM, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression. Blood. 2015;125:1394\u2013402.","journal-title":"Blood."},{"key":"9098_CR6","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/17474086.2021.1955344","volume":"14","author":"K Karube","year":"2021","unstructured":"Karube K, Kakimoto Y, Tonozuka Y, Ohshima K. The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas. Expert Rev Hematol. 2021;14:777\u201387.","journal-title":"Expert Rev Hematol"},{"key":"9098_CR7","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.humpath.2018.10.025","volume":"85","author":"F Fujishima","year":"2019","unstructured":"Fujishima F, Katsushima H, Fukuhara N, Konosu-Fukaya S, Nakamura Y, Usubuchi H, et al. Immunohistochemical pattern of c-MYC protein judged as \u201c+\/(weak)+\/\u2212 \u201d by a new notation correlates with MYC gene nontranslocation in large B-cell lymphoma. Hum Pathol. 2019;85:112\u20138.","journal-title":"Hum Pathol"},{"key":"9098_CR8","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood-2016-12-759621","volume":"130","author":"N Tsuyama","year":"2017","unstructured":"Tsuyama N, Sakata S, Baba S, Mishima Y, Nishimura N, Ueda K, et al. BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation. Blood. 2017;130:489\u2013500.","journal-title":"Blood."},{"key":"9098_CR9","first-page":"1783","volume":"9","author":"MC Bene","year":"1995","unstructured":"Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9:1783\u20136.","journal-title":"Leukemia."},{"key":"9098_CR10","first-page":"1898","volume":"92","author":"WD Ludwig","year":"1998","unstructured":"Ludwig WD, Rieder H, Bartram CR, Heinze B, Schwartz S, Gassmann W, et al. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03\/87 and 04\/89. Blood. 1998;92:1898\u2013909.","journal-title":"Blood."},{"key":"9098_CR11","first-page":"154","volume":"86","author":"C Wuchter","year":"2001","unstructured":"Wuchter C, Ratei R, Spahn G, Schoch C, Harbott J, Schnittger S, et al. Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping. Haematologica. 2001;86:154\u201361.","journal-title":"Haematologica."},{"key":"9098_CR12","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3109\/10428194.2013.820293","volume":"55","author":"W Zheng","year":"2014","unstructured":"Zheng W, Medeiros LJ, Young KH, Goswami M, Powers L, Kantarjian HH, et al. CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis. Leuk Lymphoma. 2014;55:624\u20137.","journal-title":"Leuk Lymphoma."},{"key":"9098_CR13","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/hon.2482","volume":"36","author":"K Kawamoto","year":"2018","unstructured":"Kawamoto K, Miyoshi H, Suzuki T, Sasaki Y, Yamada K, Yanagida E, et al. Frequent expression of CD30 in extranodal NK\/T-cell lymphoma: potential therapeutic target for anti-CD30 antibody-based therapy. Hematol Oncol. 2018;36:166\u201373.","journal-title":"Hematol Oncol"},{"key":"9098_CR14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/cyto.b.21838","volume":"98","author":"JC Wang","year":"2020","unstructured":"Wang JC, Deng XQ, Liu WP, Gao LM, Zhang WY, Yan JQ, et al. Comprehensive flow-cytometry-based immunophenotyping analysis for accurate diagnosis and management of extranodal NK\/T cell lymphoma, nasal type. Cytometry B Clin Cytom. 2020;98:28\u201335.","journal-title":"Cytometry B Clin Cytom"},{"key":"9098_CR15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1080\/10428194.2016.1183254","volume":"58","author":"H Katsushima","year":"2017","unstructured":"Katsushima H, Fukuhara N, Ichikawa S, Ota Y, Takeuchi K, Ishizawa K, et al. Non-biased and complete case registration of lymphoid leukemia and lymphoma for five years: a first representative index of Japan from an epidemiologically stable Miyagi prefecture. Leuk Lymphoma. 2017;58:80\u20138.","journal-title":"Leuk Lymphoma"},{"key":"9098_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1620\/tjem.224.151","volume":"224","author":"Y Miura","year":"2011","unstructured":"Miura Y, Fukuhara N, Yamamoto J, Kohata K, Ishizawa K, Ichinohasama R, et al. Clinicopathological features of malignant lymphoma in Japan: the Miyagi study. Tohoku J Exp Med. 2011;224:151\u201360.","journal-title":"Tohoku J Exp Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09098-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-09098-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09098-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T14:09:00Z","timestamp":1640009340000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-09098-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["9098"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-09098-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"15 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study was approved by the ethics committee of Tohoku University Hospital (No.2019\u20131-613), Tohoku Medical and Pharmaceutical University Hospital (No.2014\u20133-006), Sendai Medical Center (No.2017\u20130616), Sendai City Hospital (No.536), Osaki Citizen Hospital (No.2009\u20130825) and Miyagi Cancer Center (No.23\u201314). In Ishinomaki Red Cross Hospital, it is approved by IRB, which refers to an applicable organization. We complied with the tenets of the Declaration of Helsinki, and informed consent was obtained from all patients prior to surgery.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1352"}}